IDE892Recent news mentioning IDE8922026-07-27 — IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung CancersAppears alongsideIDEAYAPRMT5Browse the full archive →